» Articles » PMID: 8026985

Complete Association of the HLA-DRB1*04 and -DQB1*04 Alleles with Vogt-Koyanagi-Harada's Disease

Overview
Journal Hum Immunol
Date 1994 Mar 1
PMID 8026985
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

VKH disease is a bilateral panuveitis and has been known to be closely associated with the particular HLA class II antigens HLA-DR4 and -DQ4, defined by serologic typing. In this study, 63 Japanese VKH patients were analyzed for HLA class II alleles at the DNA level using the PCR-RFLP method. The DRB1*04 alleles encoding the serologic specificity DR4 were found in 100% of the VKH patients carrying DRB1*0405 or DRB1*0410. By statistical analysis, only DRB1*0405 was found to be significantly increased as compared to the healthy controls (RR = 46.7 and pc < 1 x 10(-5)). As to the DQB1 locus, all the patients carried DQB1*0401 or DQB1*0402 expressing the serologic DQ4 specificity, which is in a strong linkage disequilibrium with DRB1*0405 or DRB1*0410 in a Japanese population, respectively. Only DQB1*0401 showed a statistically significant increase as compared to the healthy controls (RR = 41.3 and pc < 1 x 10(-5)). Comparison of the amino acid sequences of these DRB1 and DQB1 alleles indicates that Ser at position 57 of DRB1 and/or Glu at position 70 and Asp at position 71 of DQB1 plays a crucial role in determining the susceptibility to VKH disease.

Citing Articles

Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review.

Zhang H, Houadj L, Wu K, Tran S Diagnostics (Basel). 2024; 14(3).

PMID: 38337852 PMC: 10855398. DOI: 10.3390/diagnostics14030336.


HLA-DRB1*04:05 is involved in the development of Vogt-Koyanagi-Harada disease-like immune-related adverse events in patients receiving immune checkpoint inhibitors.

Takeuchi M, Meguro A, Nakamura J, Chikagawa R, Osada R, Shibuya E Sci Rep. 2023; 13(1):13580.

PMID: 37604934 PMC: 10442432. DOI: 10.1038/s41598-023-40565-z.


A COVID-19 perspective of Vogt-Koyanagi-Harada disease.

Dutta Majumder P, Sadhu S, Gonzalez-Lopez J, Mochizuki M Indian J Ophthalmol. 2023; 71(6):2587-2591.

PMID: 37322685 PMC: 10417979. DOI: 10.4103/IJO.IJO_172_23.


Adalimumab treatment for chronic recurrent Vogt-Koyanagi-Harada disease with sunset glow fundus: A multicenter study.

Takeuchi M, Nakai S, Usui Y, Namba K, Suzuki K, Harada Y Saudi J Ophthalmol. 2023; 36(4):380-386.

PMID: 36618573 PMC: 9811924. DOI: 10.4103/sjopt.sjopt_204_22.


Outcomes of patients with acute Vogt-Koyanagi-Harada disease treated with intravenous corticosteroid pulse followed by the slow tapering of oral corticosteroid therapy.

Fushitsu R, Ishibazawa A, Murono M, Kinouchi R Int Ophthalmol. 2022; 43(2):431-440.

PMID: 35869402 DOI: 10.1007/s10792-022-02440-0.